National Cancer Institute (NCI)s

National Cancer Institute (NCI)

444 Protocols (228 Active Accrual of new subjects, 216 Follow-up of previously enrolled subjects)

 000274-C:

Phase I Trial of Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

 000264-C:

A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response

 000176-C:

A Phase I/II Trial of Lurbinectedin with Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High Grade Neuroendocrine Cancers

 000144-C:

A Phase I/II Study of Sacituzumab Govitecan plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

 000114-C:

A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination with the Immunocytokine M9241 in Localized High and Intermediate Risk Prostate Cancer Treated with Androgen Deprivation Therapy

 000103-C:

A Randomized Study Investigating the Pharmacokinetics of Standard Interval Dosing Compared to Extended Interval Dosing of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers

 000092-C:

Phase 1/2 study of Vincristine and Temozolomide in Combination with PEN-866 for Adolescents and Young Adults with Relapsed or Refractory Solid Tumors

 000048-C:

A Multi-Center Natural History Study of Precision-Based Genomics in Prostate Cancer

 22-C-0005:

Phase I Dose Escalation and Expansion Study of Tazemetostat in Combination with Topotecan and Pembrolizumab in Recurrent Small Cell Lung Cancer

 22-C-0004:

A Phase II Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer

 22-C-0003:

Feasibility of Evaluating Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis

 21-C-0030:

Phase I Study of GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC)

 21-C-0026:

A Phase I/II Study of Abemaciclib in Patients with HIV-associated and HIV-negative Kaposi Sarcoma

 21-C-0023:

A Phase I Study of Pomalidomide and Nivolumab in Patients with Virus-Associated Malignancies with or without HIV

 21-C-0019:

Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients with Relapsed/Refractory Hairy Cell Leukemia and Variant

 21-C-0017:

Magnetic Resonance Image (MRI) Guided High Energy Ultrasound for Focal Prostate Cancer Ablation

 21-C-0014:

Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

 21-C-0012:

Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis from Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies

 21-C-0011:

A Phase 0/I/II Study of the Cyclin-Dependent Kinase(CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type 1 (NF1) Related Atypical Neurofibromas

 21-C-0009:

A Natural History Study of Children and Adults with Olfactory Neuroblastoma

 21-C-0006:

Phase II Study Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers

 21-C-0001:

A Phase I/II Study of M9241 with Docetaxel and Abiraterone in Adults with Metastatic Castration Sensitive and M9241 with Docetaxel in Castration Resistant Prostate Cancer

 20-C-0164:

Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer

 20-C-0161:

Prospective Study of Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis

 20-C-0121:

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

 20-C-0107:

Clinical, Genetic, and Epidemiologic Study of Children and Adults with RASopathies

 20-C-0106:

Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients with BAP1 Tumor Predisposition Syndrome

 20-C-0097:

A Phase II, Open-Label Trial of Bintrafusp Alfa (M7824) in Subjects with Thymoma and Thymic Carcinoma

 20-C-0076:

Phase 2 Trial of Encorafenib plus Binimetinib for Patients with BRAF V600 Mutated Relapsed/Refractory HCL

 20-C-0075:

Phase 2 Trial for Binimetinib for Patients with Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant

 20-C-0070:

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Patients with Inborn Errors of Immunity

 20-C-0069:

A First-In-Human Phase I Single-Agent Dose-Escalation and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

 20-C-0062:

A phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)

 20-C-0061:

Phase I/II study of PDS01ADC Monotherapy and in Combination with M7824 in Advanced Kaposi Sarcoma

 20-C-0051:

Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies

 20-C-0023:

First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects with Metastatic Solid Tumors

 20-C-0020:

Ex-Vivo Trial of En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device

 20-C-0012:

A Phase I Study of Bintrafusp alfa (M7824) and PDS01ADC Alone and in Combination with Stereotactic Body Radiation Therapy (SBRT) in Adults with Metastatic Non-Prostate Genitourinary Malignancies

 20-C-0010:

Phase II Trial of Radium-223 in Biochemically Recurrent Prostate Cancer

 20-C-0006:

A National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer (PLC)

 19-C-0138:

Phase I/II Study of Lu-177-DOTATATE (Lutathera) in Combination with Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

 19-C-0137:

A Phase II Study of Ipilimumab, Cabozantinib, and NIvolumab in Rare Genitourinary Cancers (ICONIC)

 19-C-0135:

Evaluation of the Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

 19-C-0131:

Development and Psychometric Testing of a Pediatric Chronic Graft- Versus-Host Disease (GVHD) Symptom Scale (PCSS)

 19-C-0123:

DURVA PLUS: Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination with Chemotherapy in Patients with Advanced Solid Tumors

 19-C-0116:

A Phase 2 Study of Acalabrutinib with DA-EPOCH-R or R-CHOP for Patients with Untreated Diffuse Large B-cell Lymphoma

 19-C-0112:

Phase I/II Study De-intensifying Exposure of Post-transplantation Cyclophosphamide as GVHD Prophylaxis after HLA-haploidentical Hematopoietic Cell Transplantation for Hematologic Malignancies

 19-C-0096:

Studying the Biology of Higher-Grade Transformation in IDH-mutant Gliomas via Longitudinal Observation of Tumor Metabolic Reprogramming Using Non-invasive Metabolic Imaging

 19-C-0085:

Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Peripheral T cell Lymphoma

 19-C-0082:

Natural History Study of Children and Adults with Chordoma

 19-C-0049:

Long Term Follow-up of Mesothelioma Patients and Their Family Members with Germline Mutations in BAP1 and Other Genes

 19-C-0040:

Natural History Study of Men at High Genetic Risk for Prostate Cancer

 19-C-0025:

Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies

 19-C-0023:

A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma and other genitourinary tumors with DNA-Repair Defects

 19-C-0017:

A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

 19-C-0016:

Natural History and Biospecimen Acquisition Study for Children and Adults with Rare Solid Tumors

 18-DC-0051:

Biospecimen Procurement for the Study of Head and Neck Disorders

 18-C-0147:

Phase 1 with Expansion Cohorts in a Study of NEO-201 In Adults with Chemo-Resistant Solid Tumors

 18-C-0049:

A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients with Metastatic Cancer

 18-C-0017:

Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer

 18-C-0014:

Phase I Trial of 5-aza-4'-thio-2'-Deoxycytidine (Aza-TdC) in Patients with Advanced Solid Tumors

 17-C-0174:

Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease

 17-C-0156:

Longitudinal Sample Collection and Tracking for the Developmental Therapeutics Clinic, National Cancer Institute

 17-C-0137:

Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing

 17-C-0127:

Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

 17-C-0125:

Phase 2 Trial of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas

 17-C-0113:

A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

 17-C-0109:

18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

 17-C-0105:

Prospective Study of Clonal Evolution in Follicular Lymphoma

 17-C-0087:

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

 17-C-0027:

Long-Term Follow up of Patients Undergoing Hematopoietic Stem Cell Transplantation

 16-C-0138:

Collection of Peripheral Blood Mononuclear Cells (PBMCs) from Healthy Subjects for the Expansion of T Cells for Adoptive Cell Therapy

 16-C-0131:

A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a CD70-Binding Chimeric Antigen Receptor to Patients with CD70-Expressing Cancers

 16-C-0076:

Prospective Screening for Patient Specific Genotypes and Phenotypes that Influence Drug Dosing and Trial Selection in Cancer Patients

 16-C-0061:

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

 16-C-0027:

A Phase II Trial for Metastatic Melanoma Using Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

 16-C-0010:

Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue

 16-C-0003:

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies

 15-C-0195:

Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals with Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)

 15-C-0141:

Gene Therapy Follow up Protocol for Subjects Previously Enrolled in CAR T-Cell Studies

 15-C-0093:

Phase I Trial of TURALIO (pexidartinib, PLX3397) in Children and Young Adults with Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor (TGCT

 15-C-0087:

Care of the Urothelial Cancer Patient and Prospective Collection of Biospecimens from Healthy Volunteers and Urothelial Cancer Patients

 15-C-0086:

Phase I Trial of the Combination of Nilotinib and Paclitaxel in Adults and Pediatric Patients with Refractory Solid Tumors

 15-C-0028:

Follow-Up Evaluation for Gene-Therapy Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials

 14-C-0157:

Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (TEDDI-R) in Primary CNS Lymphoma

 14-C-0128:

Collection of Pharmacokinetic and Probe Substrate Samples from Participants with Unanticipated Response, Significant Toxicity or Concern of Future Toxicity

 14-C-0105:

Tissue Procurement and Natural History Study of Patients with Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

 14-C-0104:

A Phase II Study Using Autologous Young Tumor-Infiltrating Lymphocytes Derived from Patients with Non-Small Cell Lung Cancer Following Non-Myeloablative Lymphocyte Depleting Preparative Regimen

 13-C-0202:

Tissue Procurement and Natural History Study of Patients with Malignant Mesothelioma and Other Mesothelin Expressing Cancers

 13-C-0176:

Tumor, Normal Tissue and Specimens from Patients Undergoing Evaluation or Surgical Resection of Solid Tumors

 13-C-0132:

Allogeneic Hematopoietic Stem Cell Transplant for Patients with Mutations in GATA2 or the MonoMAC Syndrome

 13-C-0131:

Inpatient Hospice with Procurement of Tissue on Expiration in Thoracic Malignancies, Bladder Cancer, Ovarian Cancer, Epithelial Cancer and Patients Treated with an Adoptive Cellular Therapy

 13-C-0119:

Evaluation of Local Response of Prostate Cancer to Irradiation Using Multiparametric MRI and MR-Guided Biopsies

 12-C-0193:

Lymphoid Malignancies and Precursors: Tissue Acquisition Protocol

 12-C-0178:

Longitudinal Assessment and Natural History Study of Children and Adults with MEN2A or MEN2B with or without Medullary Thyroid Carcinoma

 11-C-0255:

Clinical, Epidemiologic, and Genetic Studies of Li-Fraumeni Syndrome

 11-C-0242:

Collection of Blood from Therapeutic Trial Participants for Analysis of Genetic Differences in Drug Disposition and Pharmacokinetics of Probe Medications

 11-C-0220:

Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)

 11-C-0112:

Acquisition of Data, Blood, and Tumor Tissue Samples from Patients with Gastrointestinal Cancer

 11-C-0034:

DICER1-Related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study

Previous 100 Protocols

Next -200 Protocols